Overview

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Myeloablative conditioning using a dose escalation of clofarabine in combination with cytarabine (ARA-C) and total body irradiation (TBI) will lead to improved survival for previously untransplanted children and adolescents with acute lymphoblastic leukemia (ALL) and acute non-lymphoblastic leukemia (ANLL)followed by allogeneic stem cell transplantation (AlloSCT).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York Medical College
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Clofarabine